The development of new therapies for diseases of the immune system is a key priority for Boehringer Ingelheim. Our robust Immunology research and development pipeline is firmly anchored by a panel of external collaborations to deliver promising new compounds with the potential to transform the treatment of immune-mediated diseases.

Our Immunology partnering focus
We are seeking collaboration and in-licensing opportunities from early research stage through late pre-clinical development in the following areas:

- Crohn’s disease: including specific approaches for fistulizing and refractory ileal Crohn’s disease
- Ulcerative colitis
- Inflammatory skin diseases: including systemic sclerosis-scleroderma.

Within these areas, our specific research interests offer further opportunities for collaboration:

- Human genetics: identification of new therapeutic concepts and biomarkers
- Gut & skin epithelial barrier dysfunction: regulation of injury, inflammation and repair, including host-microbiome interactions
- Control of aberrant tissue remodeling and fibrosis
- Innate immune signaling pathways
- Immune regulatory receptors.

If you share our goal of researching and developing new medications to improve the health of people around the world please join us in...

Working together for better health

For more information please contact our BD&L team:
Dr. Andrew Hutchinson
andrew.hutchinson@boehringer-ingelheim.com